Effect of Hemoglobin Levels on Cardiovascular Outcomes in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy (from the LIFE Study)

American Journal of Cardiology

Volumn 100, Issue 5, 2007, Pages 855-859

  Smebye, Marianne L ^a   Iversen, Emil K ^a   Høieggen, Aud ^a   Flaa, Arnljot ^a   Os, Ingrid ^a   Kjeldsen, Sverre E ^a,b   Olsen, Michael Hecht ^c   Chattopadhyay, Arghya ^d   Hille, Darcy A ^d   Lyle, Paulette A ^d   Devereux, Richard B ^e   Dahlöf, Björn ^f  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF MICHIGAN   (United States)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Department of Molecular Biology and Genetics   (United States)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; HEMOGLOBIN; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCORING SYSTEM; STROKE; SYSTOLIC HYPERTENSION; TIME;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 34547934432     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.03.109     Document Type: Article

References (21)

1. Fossum E., Hoieggen A., Moan A., Nordby G., Velund T.L., and Kjeldsen S.E. Whole blood viscosity, blood pressure and cardiovascular risk factors in healthy blood donors. Blood Press 6 (1997) 161-165
2. Folkow B. The fourth Volhard lecture: cardiovascular structural adaptation; its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med 4 suppl (1978) 3s-22s
3. Erikssen G., Thaulow E., Sandvik L., Stormorken H., and Erikssen J. Haematocrit: a predictor of cardiovascular mortality?. J Intern Med 234 (1993) 493-499
4. Devereux R.B., Drayer J.I., Chien S., Pickering T.G., Letcher R.L., DeYoung J.L., Sealey J.E., and Laragh J.H. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 54 (1984) 592-595
5. Sarnak M.J., Tighiouart H., Manjunath G., MacLeod B., Griffith J., Salem D., and Levey A.S. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 40 (2002) 27-33
6. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107 (2003) 223-225
7. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
8. Dahlöf B., Devereux R., de Faire U., Fyhrquist F., Hedner T., Ibsen H., Julius S., Kjeldsen S., Kristianson K., Lederballe-Pedersen O., et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 10 7 pt 1 (1997) 705-713
9. Dahlöf B., Devereux R.B., Julius S., Kjeldsen S.E., Beevers G., de Faire U., Fyhrquist F., Hedner T., Ibsen H., Kristianson K., et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 32 (1998) 989-997
10. Lindholm L.H., Ibsen H., Dahlöf B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., et al., LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
11. Kjeldsen S.E., Dahlöf B., Devereux R.B., Julius S., de Faire U., Fyhrquist F., Ibsen H., Kristianson K., Lederballe-Pedersen O., Lindholm L.H., et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens 13 (2000) 899-906
12. Kjeldsen S.E., Dahlöf B., Devereux R.B., Julius S., Aurup P., Edelman J., Beevers G., de Faire U., Fyhrquist F., Ibsen H., et al., LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288 (2002) 1491-1498
13. Molloy T.J., Okin P.M., Devereux R.B., and Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 20 (1992) 1180-1186
14. Okin P.M., Roman M.J., Devereux R.B., and Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 25 (1995) 417-423
15. Sokolow M., and Lyon T.P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. 1949. Ann Noninvasive Electrocardiol 6 (2001) 343-368
16. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
17. Robles N.R., Angulo E., Grois J., and Barquero A. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. Ren Fail 26 (2004) 399-404
18. Olsen M.H., Wachtell K., Beevers G., Dahlöf B., Devereux R.B., de Faire U., Fyhrquist F., Ibsen H., Kjeldsen S.E., Lederballe-Pedersen O., et al. High hemoglobin was associated with cardiovascular events, low hemoglobin with all-cause mortality, and large fall in hemoglobin with both in patients with hypertension and left ventricular hypertrophy: The LIFE study. J Am Coll Cardiol 47 suppl (2006) 361A
19. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 405 (1968) 5-37
20. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., Burger H.U., Scherhag A., and CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
21. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., Reddan D., and CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 16 (2006) 2085-2098